Skip to main content

Johnson & Johnson(JNJ-N)
NYSE

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low224.70
Day High229.69
Open:229.35
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
the globe and mail
FILE - Johnson & Johnson Consumer Health in Flourtown, Pa., Friday, April 28, 2023. A subsidiary of Johnson & Johnson is now proposing paying approximately $6.48 billion over 25 years as part of a settlement to cover allegations that its baby powder containing talc caused ovarian cancer. J&J said that the reorganization plan for the subsidiary that was being announced on Wednesday, May 1, 2024, was significantly different from the previous reorganization that was announced. (AP Photo/Matt Rourke)
the globe and mail

J&J’s first-quarter profit beats estimates even as Stelara sales disappoint

Drug and device maker raised its full-year revenue and adjusted earnings forecast
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
MarketBeat
3 Giant Dividend Stocks Raising Payouts With Yields Up to 4%
MarketBeat.com
Motley Fool
Could This Healthcare Stock Help Make You Rich Over the Next Decade?
Motley Fool
Is Johnson & Johnson a Buy After Its Q1 2026 Earnings Report?
Motley Fool
3 Catalysts That Could Send Teva Stock to $40 and Beyond
Zacks Investment Research
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
AbbVie Trades Below 50-Day and 200-Day SMA: How to Play the Stock
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ), Zealand Pharma (OtherZLDPF) and Camurus AB (OtherCAMRF)
Tipranks
Analysts Have Conflicting Sentiments on These Healthcare Companies: Verrica Pharmaceuticals (VRCA) and Johnson & Johnson (JNJ)
Motley Fool
3 Under-the-Radar Healthcare Stocks Worth Adding to Your Watchlist
Motley Fool
This "Boring" Dividend King Is Quietly Turning Into a Growth Machine
Motley Fool
3 Healthcare Stocks That Have Held Up in Every Market Downturn
MarketBeat
Skip the 10-Year Bond? 3 Dividend Aristocrats to Consider Now
MarketBeat.com
GlobeNewswire
The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
Zacks Investment Research
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
J&J Targets Double-Digit Growth by 2030 Despite Stelara Drag
Tipranks
Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Vertex Pharmaceuticals (VRTX)
Tipranks
Analysts Offer Insights on Healthcare Companies: AbCellera Biologics (ABCL), Telix Pharmaceuticals (OtherTLPPF) and Johnson & Johnson (JNJ)
Tipranks
Morgan Stanley Sticks to Its Buy Rating for Johnson & Johnson (JNJ)
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Tipranks
Goldman Sachs Reaffirms Their Buy Rating on Johnson & Johnson (JNJ)
Tipranks
Johnson & Johnson (JNJ) Gets a Buy from Wells Fargo
Tipranks
Johnson & Johnson Bets Big on Next-Gen Growth
Stock Target Advisor
Safest Stocks to Consider in Today’s Market
Safest Stocks to Consider in Today’s Market
Stock Target Advisor
Stocks Surge Again on Oil Drop and Iran Deal Hope-Global Markets for April 14th, 2026
Stocks Surge Again on Oil Drop and Iran Deal Hope-Global Markets for April 14th, 2026
Tipranks
Johnson & Johnson boosts outlook and raises dividend
Tipranks
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH), Recursion Pharmaceuticals (RXRX) and Johnson & Johnson (JNJ)
Motley Fool
What Makes a Healthcare Stock Worth Holding Through a Recession?
MarketBeat
Johnson & Johnson: A 20% Gain Looks Easy After Q1 Earnings Results
MarketBeat.com
Tipranks
Analysts Conflicted on These Healthcare Names: Johnson & Johnson (JNJ), BeOne Medicines (ONC) and Helus Pharma (HELP)
Zacks Investment Research
Pre-Markets Down as U.S. Sets Blockade at Hormuz
Pre-Markets Down as U.S. Sets Blockade at Hormuz
Zacks Investment Research
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Will AbbVie's Neuroscience Franchise Aid Top-line Growth in Q1?
Baystreet
Wholesale Inflation on Agenda for Next Week
Motley Fool
Which Dividend Pharma Stock Should a Value Investor Choose Today?

Profile

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.